# COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

> **NCT04510194** · PHASE3 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 1323 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo
- **DRUG:** Fluvoxamine
- **DRUG:** Ivermectin

## Key facts

- **NCT ID:** NCT04510194
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 1323 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510194, "COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04510194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*